FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
|Articles|January 1, 2007
Plop, Plop, Fizz, Fizz-and You Can Be a Workout Whiz
When patients cite muscle pain anddiscomfort as an excuse for not exercisingregularly, suggest they try anapproach that athletes use.
Advertisement
When patients cite muscle pain and discomfort as an excuse for not exercising regularly, suggest they try an approach that athletes use. Taking Alka-Seltzer after working out can make muscle-building less painful. Alka-Seltzer contains sodium bicarbonate and aspirin; the sodium bicarbonate alkalinizes the lactic acid produced by the muscles during exertion, and the aspirin helps ease the pain while the kidneys flush the toxins. Do not recommend this use of Alka-Seltzer to patients who are allergic to any of its ingredients, or to those with kidney problems.
- Debra M. Monde, DO
Abilene, Tex
Advertisement
Related to this article
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
New American Society of Hematology guidelines raise ferritin cutoffs to catch iron deficiency sooner, including pregnancy and inflammation, and add TSAT for clearer diagnosis.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
Advertisement
Advertisement
Trending on Patient Care Online
1
Lumateperone Reduces Acute Mania Symptoms in Phase 3 Bipolar I Trial
2
FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH
3
Endocrine Society Obesity Statement Calls for Goals Beyond Weight Loss
4
Clinical Inertia and Poor Measurement Technique Undermine BP Control
5